[go: up one dir, main page]

BR9809288A - Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas - Google Patents

Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas

Info

Publication number
BR9809288A
BR9809288A BR9809288-0A BR9809288A BR9809288A BR 9809288 A BR9809288 A BR 9809288A BR 9809288 A BR9809288 A BR 9809288A BR 9809288 A BR9809288 A BR 9809288A
Authority
BR
Brazil
Prior art keywords
treatment
prevention
thiosemicarbazones
aryl
heterocycle
Prior art date
Application number
BR9809288-0A
Other languages
English (en)
Inventor
Yan Wang
Sui Xiong Cai
Nancy C Lan
John F W Keana
Victor I Ilyin
Eckard Weber
Original Assignee
Cocensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocensys Inc filed Critical Cocensys Inc
Publication of BR9809288A publication Critical patent/BR9809288A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
    • C07C281/12—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being part of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C07C281/08—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones
    • C07C281/14—Compounds containing any of the groups, e.g. semicarbazides the other nitrogen atom being further doubly-bound to a carbon atom, e.g. semicarbazones the carbon atom being further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"SEMICARBAZONAS E TIOSEMICARBAZONAS SUBSTITUìDAS CARBOCìCLICAS E HETEROCìCLICAS E UTILIZAçãO DAS MESMAS" Esta invenção está relacionada as semicarbazonas e tiosemicarbazonas substituídas carbocíclicas e heterocíclicas representadas pela fórmula (I), ou um sal farmaceuticamente aceitável ou pró-medicamento das mesmas, onde: Y é oxigênio ou enxofre; R~ 1~ R~ 21~, R~ 22~ e R~ 23~ são independentemente hidrogênio, alquila, cicloalquila, alquenila, alquinila, haloalquila, arila, aminoalquila, hidroxialquila, alcoxialquila ou carboxialquila ou R~ 22~ e R~ 23~ juntamente com N formam um heterociclo; A~ 1~ e A~ 2~ são independentemente arila, heteroarila, carbociclo saturado ou parcialmente insaturado ou heterociclo saturado ou parcialmente insaturado, qualquer um dos quais é opcionalmente substituído; X é um ou O, S, NR~ 24~, CR~ 25~R~ 26~, C(O), NR~ 24~C(O), C(O)NR~ 24~, SO, SO~ 2~ ou uma ligação covalente; onde R~ 24~, R~ 25~ e R~ 26~ são independentemente hidrogênio, alquila, cicloalquila, alquenila, alquinila, haloalquila, arila, aminoalquila, hidroxialquila, alcoxialquila ou carboxialquila. A invenção é também dirigida ao uso de semicarbazonas e tiosemicarbazonas substituídas carbociclo e heterociclo para o tratamento de distúrbios neuronais seguindo a isquemia global ou focal, para o tratamento ou prevenção de condições neurodegenerativas, tais como, esclerose lamiotrófica lateral (ALS), para o tratamento e prevenção de otoneurotoxicidade e doenças oculares envolvendo toxicidade por glutamato e para o tratamento, prevenção ou melhora de dor, como anti-convulsivos e como anti-maníacos depressivos, como anestésicos locais, como anti-arritmícos e para o tratamento e prevenção de neuropatia diabética e incontinência urinária.
BR9809288-0A 1997-04-22 1998-04-22 Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas BR9809288A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4453097P 1997-04-22 1997-04-22
US6264997P 1997-10-22 1997-10-22
PCT/US1998/008004 WO1998047869A1 (en) 1997-04-22 1998-04-22 Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof

Publications (1)

Publication Number Publication Date
BR9809288A true BR9809288A (pt) 2001-08-07

Family

ID=26721676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809288-0A BR9809288A (pt) 1997-04-22 1998-04-22 Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas

Country Status (13)

Country Link
US (4) US6613803B1 (pt)
EP (1) EP0986540B1 (pt)
JP (1) JP2001526648A (pt)
KR (1) KR20010020201A (pt)
AT (1) ATE289295T1 (pt)
AU (1) AU738197C (pt)
BR (1) BR9809288A (pt)
CA (1) CA2287255A1 (pt)
DE (1) DE69829048T2 (pt)
IL (1) IL132522A0 (pt)
NO (1) NO995094L (pt)
NZ (1) NZ500590A (pt)
WO (1) WO1998047869A1 (pt)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
BR9809288A (pt) * 1997-04-22 2001-08-07 Cocensys Inc Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas
WO1999026614A1 (en) 1997-11-21 1999-06-03 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
US6281211B1 (en) 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
EP1169060B1 (en) * 1999-04-09 2005-08-31 Euro-Celtique S.A. Sodium channel blocker compositions and the use thereof
AU758207B2 (en) * 1999-05-28 2003-03-20 Cj Cheiljedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
EP1311482B1 (en) * 2000-08-08 2007-02-21 Ortho-McNeil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
EA200300508A1 (ru) * 2000-10-26 2004-06-24 Туларик Инк. Противовоспалительные агенты
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
EP1392219A4 (en) 2001-05-10 2007-01-24 Cytovia Inc SUBSTITUTED N '- (ARYLCARBONYL) -BENZYLIDENE-HYDRAZIDE N' - (ARYLCARBONYL) -BENZHYDRAZIDES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS AND USE THEREOF
US6831193B2 (en) 2001-05-18 2004-12-14 Abbott Laboratories Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
ATE304523T1 (de) * 2001-05-18 2005-09-15 Abbott Lab Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1- naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
WO2002098420A1 (en) * 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2003020273A2 (en) 2001-09-03 2003-03-13 Newron Pharmaceuticals Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
US7521062B2 (en) * 2002-12-27 2009-04-21 Novartis Vaccines & Diagnostics, Inc. Thiosemicarbazones as anti-virals and immunopotentiators
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
CA2525298A1 (en) * 2003-05-01 2004-11-18 Panacea Pharmaceuticals, Inc. Methods of treating ischemic related conditions
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
US8053431B2 (en) * 2005-11-01 2011-11-08 High Point Pharmaceuticals, Llc Pharmaceutical use of substituted amides
JP2009514818A (ja) * 2005-11-01 2009-04-09 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの製薬学的用途
CA2642273C (en) 2006-02-14 2016-09-20 President And Fellows Of Harvard College Bifunctional histone deacetylase inhibitors
JP5409015B2 (ja) 2006-02-14 2014-02-05 プレジデント アンド フェロウズ オブ ハーバード カレッジ ヒストンデアセチラーゼ阻害剤
WO2007107550A1 (en) * 2006-03-21 2007-09-27 High Point Pharmaceuticals, Llc Adamantane derivatives for the treatment of the metabolic syndrome
BRPI0710669A2 (pt) 2006-04-07 2011-08-16 High Point Pharmaceuticals Llc compostos ativos de dehidrogenase de 11b-hidroxiesteróide tipo 1
CN101484156B (zh) 2006-05-03 2015-11-25 哈佛大学校长及研究员协会 组蛋白脱乙酰基酶和微管蛋白脱乙酰基酶抑制剂
WO2007144394A2 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc. Pharmaceutical use of substituted piperidine carboxamides
US8048908B2 (en) * 2006-07-13 2011-11-01 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (en) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2008101885A1 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008101914A2 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EP2129652A2 (en) * 2007-02-23 2009-12-09 High Point Pharmaceuticals, LLC N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EP2125704A1 (en) * 2007-02-23 2009-12-02 High Point Pharmaceuticals, LLC N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EA200970841A1 (ru) * 2007-03-09 2010-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Фармацевтическое применение замещенных амидов
JP2010522766A (ja) * 2007-03-28 2010-07-08 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー １１ベータ−ｈｓｄ１活性化合物
EP2152081B1 (en) * 2007-04-11 2012-10-24 High Point Pharmaceuticals, LLC Novel compounds
CN101711106B (zh) * 2007-04-24 2013-02-06 高点制药有限责任公司 取代的酰胺类的药物应用
EP2532643A1 (en) 2007-06-08 2012-12-12 MannKind Corporation IRE-1A Inhibitors
WO2009052116A1 (en) * 2007-10-15 2009-04-23 The Salk Institute For Biological Studies Methods for treating a variety of diseases and conditions, and compounds useful therefor
EP2321264B1 (en) * 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
DE102008053242A1 (de) 2008-10-25 2010-05-06 Saltigo Gmbh Heteroaryl-Arylether
EA020496B1 (ru) * 2008-11-21 2014-11-28 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Производное адамантилбензамида, фармацевтическая композиция, включающая его, и его применение
US8716344B2 (en) 2009-08-11 2014-05-06 President And Fellows Of Harvard College Class- and isoform-specific HDAC inhibitors and uses thereof
EP2287149A1 (en) 2009-08-20 2011-02-23 Max-Delbrück-Centrum Für Molekulare Medizin Enhancers of protein degradation
DE102010020882A1 (de) 2010-05-18 2011-11-24 Alzchem Trostberg Gmbh Semicarbazone zur Härtung von Epoxidharzen
JP2013530180A (ja) 2010-06-16 2013-07-25 パーデュー、ファーマ、リミテッド、パートナーシップ アリール置換インドールおよびその使用
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
MX2013003101A (es) 2010-09-17 2013-09-26 Purdue Pharma Lp Compuestos de piridina y sus usos.
WO2012046132A1 (en) 2010-10-05 2012-04-12 Purdue Pharma L.P. Quinazoline compounds as sodium channel blockers
UY33766A (es) 2010-12-06 2012-06-29 Glaxo Group Ltd COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2
US9656959B2 (en) 2010-12-22 2017-05-23 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2013030665A1 (en) 2011-09-02 2013-03-07 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
US9181185B2 (en) 2011-10-31 2015-11-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
AU2012321111A1 (en) 2011-10-31 2013-05-16 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
DE102011118501A1 (de) 2011-11-15 2013-05-16 Alzchem Ag Alkyl- oder Dialkyl-Semicarbazone als Härter für Epoxidharze
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
EP2872125A4 (en) 2012-07-10 2016-02-24 Dana Farber Cancer Inst Inc ANTIPROLIFERATIVE COMPOUNDS AND USES THEREOF
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
US9637458B2 (en) 2013-03-04 2017-05-02 Jeffrey Lockman Pyrimidine carboxamides as sodium channel blockers
WO2014151393A2 (en) 2013-03-15 2014-09-25 Purdue Pharma L.P. Carboxamide derivatives and use thereof
BR112015027704B1 (pt) 2013-05-01 2021-04-06 Neoculi Pty Ltd Composto, uso do mesmo e composição farmacêutica antibacteriana
WO2015031036A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5] decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
WO2015094443A1 (en) 2013-12-20 2015-06-25 Purdue Pharma L.P. Pyrimidines and use thereof
CN106103415B (zh) 2013-12-23 2023-02-24 普渡制药公司 吲唑和其用途
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
WO2015102682A1 (en) 2013-12-30 2015-07-09 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
JP6526023B2 (ja) 2014-01-24 2019-06-05 パーデュー、ファーマ、リミテッド、パートナーシップ ピリジン類及びピリミジン類並びにその使用
AU2015217185B2 (en) 2014-02-12 2018-04-05 Purdue Pharma L.P. Isoquinoline derivatives and use thereof
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
MA39956A (fr) 2014-05-06 2015-11-12 Purdue Pharma Lp Analogues du benzomorphane et leur utilisation
WO2015192053A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
EP3154971A4 (en) 2014-06-13 2017-11-01 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE667022A (pt)
DE303837C (pt)
US3255241A (en) 1961-01-19 1966-06-07 Merck & Co Inc (2-alkylidene acyl)phenoxy-and (2-alkylidene acyl)phenylmercaptocarboxylic acids
NL273765A (pt) 1961-01-19
BE622079A (pt) 1961-09-11
US3251064A (en) 1962-11-13 1966-05-10 Everett M Schultz beta-aminoacylphenoxy-and beta-aminoacylphenylmercapto-derivatives of monocarboxylicacids
NL300456A (pt) 1962-11-13
BE643709A (pt) 1963-02-12 1900-01-01
DE1288086B (pt) 1963-12-26 1969-01-30
US3304323A (en) 1964-03-20 1967-02-14 Upjohn Co Oxygenated dicycloalkyl sulfones
US3392171A (en) 1964-03-20 1968-07-09 Upjohn Co 4-morpholino-4'-hydroxy bicyclohexyls
US3303214A (en) 1964-05-13 1967-02-07 Wallace & Tiernan Inc Nitrososemicarbazides
NL128632C (pt) 1964-07-17
GB1164608A (en) 1966-08-23 1969-09-17 May & Baker Ltd Semicarbazone and Thiosemicarbazone Quaternary Salts
US3712914A (en) 1970-05-14 1973-01-23 Stauffer Chemical Co Arylidene semicarbizides
DE2420618C2 (de) 1974-04-27 1982-09-16 C.H. Boehringer Sohn, 6507 Ingelheim Aminoalkylanilide, Verfahren zu ihrer Herstellung sowie pharmazeutische Zubereitungen, die diese Aminoalkylanilide enthalten
US4394514A (en) 1981-04-30 1983-07-19 Smithkline Beckman Corporation Processes for preparing 4-substituted indoles
US5266585A (en) 1981-05-12 1993-11-30 Ciba-Geigy Corporation Arylphenyl ether derivatives, compositions containing these compounds and use thereof
FI77458C (fi) 1981-05-12 1989-03-10 Ciba Geigy Ag Nya mikrobicida arylfenyleterderivat, foerfarande foer deras framstaellning och deras anvaendning.
US4454337A (en) 1981-06-29 1984-06-12 Smithkline Beckman Corporation Semicarbazide intermediates for preparing 4-substituted indoles
ATE61797T1 (de) 1985-08-20 1991-04-15 Sandoz Ag Semicarbazone und thiosemicarbazone.
US5098466A (en) 1985-08-20 1992-03-24 Sandoz Ltd. Compounds
PT86407B (pt) 1986-12-31 1990-11-20 Fujisawa Pharmaceutical Co Processo para a preparacao de novos derivados de alcano-sulfonanilida, e de composicoes farmaceuticas compreendendo os mesmos
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US4971986A (en) 1988-03-25 1990-11-20 Ciba-Geigy Corporation Arylhydrazones useful as SAMDC inhibitors
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
DE4033808A1 (de) 1990-04-11 1991-10-17 Bayer Ag Naphthalinderivate
GB9102423D0 (en) 1991-02-05 1991-03-20 Ciba Geigy Ag Pryimidinyl-and triazinylsalicyl-and-picolinylaldehyde derivatives
WO1994006758A1 (en) * 1992-09-21 1994-03-31 University Of Saskatchewan Aryl semicarbazone anticonvulsants
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
HUT71609A (en) 1993-11-25 1996-01-29 Ciba Geigy Ag Novel substituted thiosemicabazonethiones, process for preparing them and pharmaceutical compositions containing them
FR2713486B1 (fr) 1993-12-14 1996-02-09 Scophysa Nouvelles compositions pour mousses, notamment mousses rectales, et mousses ainsi obtenues.
CA2189573A1 (en) 1994-05-17 1995-11-23 Ronald E. Hackler N-(5-isothiazolyl)amide pesticides
US5741818A (en) 1995-06-07 1998-04-21 University Of Saskatchewan Semicarbazones having CNS activity and pharmaceutical preparations containing same
TR199800767T2 (xx) 1995-10-30 1998-07-21 Smithkline Beecham Corporation Proteaz engelleyicileri.
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
CA2270531C (en) 1996-11-05 2011-08-30 Head Explorer Aps A method for treating tension-type headache
WO1998043619A2 (en) 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
BR9809288A (pt) * 1997-04-22 2001-08-07 Cocensys Inc Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas
US6326020B1 (en) 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
GB9808015D0 (en) 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
EP1093348A4 (en) 1998-06-29 2003-07-16 Pharmaceuticals Applic Asociat TRANSDERMAL ANALGESIC COMPOSITIONS AND METHODS OF ADMINISTRATION
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用

Also Published As

Publication number Publication date
AU738197C (en) 2002-05-16
EP0986540B1 (en) 2005-02-16
EP0986540A4 (en) 2001-07-11
AU738197B2 (en) 2001-09-13
NO995094L (no) 1999-12-20
JP2001526648A (ja) 2001-12-18
AU7467698A (en) 1998-11-13
CA2287255A1 (en) 1998-10-29
WO1998047869A1 (en) 1998-10-29
US20020183321A1 (en) 2002-12-05
US6613803B1 (en) 2003-09-02
KR20010020201A (ko) 2001-03-15
DE69829048D1 (de) 2005-03-24
ATE289295T1 (de) 2005-03-15
US20030225080A1 (en) 2003-12-04
NO995094D0 (no) 1999-10-19
EP0986540A1 (en) 2000-03-22
IL132522A0 (en) 2001-03-19
US20020061886A1 (en) 2002-05-23
US6696442B2 (en) 2004-02-24
US6638947B2 (en) 2003-10-28
DE69829048T2 (de) 2006-02-09
NZ500590A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
BR9809288A (pt) Semicarbazonas e tiosemicarbazonas substituìdas carbocìclicas e heterocìclicas e utilização das mesmas
NO20092832L (no) Fremgangsmate for karbonylering av en forbindelse
DK1017378T3 (da) Amidderivater til behandling af sygdomme medieret af cytokiner
NO933452L (no) Et terapeutisk middel for Parkinson&#39;s sykdom
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
BR9507106A (pt) Derivado de ácido fenilacético alfa-substituido sua produção e fungicida agricola contendo o mesmo
AR026915A1 (es) Novedosas pirazolcarboxamidas y pirazoltioamidas como fungicidas
ATE282614T1 (de) Phenylharnstoff und phenylthioharnstoffderivate
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
TR199800849T2 (xx) Siklikle heterosiklik N-ikame edilmi� alfa-iminohidroksamla karbon asitleri
BRPI0116967A2 (pt) derivado de pirazina ou um sal deste, composição farmacêutica, e, derivado de fluoropirazina ou um sal deste
PT1054874E (pt) Derivados de aminofenil-isoxazolina substituidos uteis como anti-microbianos
NO971685L (no) Azolderivat
NO931317L (no) Et terapeutisk middel for parkinson&#39;s sykdom
EP0640601A4 (en) Benzamide derivative.
DE60016384D1 (de) Chondrogonese promotoren und indolin-2-on derivate
DK0551844T3 (da) Svovlholdige galdesyrederivater
ATE278701T1 (de) Malto-oligosaccharide und deren verwendung
ATE556075T1 (de) Triazoquinolone-derivate als pestizide
TH21538A (th) ซับสทิทิวเทด 2 - เฟนิลพิริดีน
MX9709275A (es) Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1877 DE 26/12/2006.